- Home
- CVBF vs TNGX Comparison
CVBF vs TNGX Comparison
Compare CVBF & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | TNGX |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CVBF | TNGX |
|---|---|---|
| Price | $22.67 | $21.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $24.50 | $21.78 |
| AVG Volume (30 Days) | 1.0M | ★ 2.1M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.95% | N/A |
| EPS Growth | 5.56 | ★ 26.89 |
| EPS | ★ 0.65 | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $21.47 | N/A |
| Revenue Next Year | $15.21 | N/A |
| P/E Ratio | $35.09 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $17.95 | $6.69 |
| 52 Week High | $23.41 | $34.39 |
Technical Indicators
Market Signals| Indicator | CVBF | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 37.46 |
| Support Level | $22.42 | $21.20 |
| Resistance Level | $23.35 | $25.64 |
| Average True Range (ATR) | 0.39 | 1.27 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 71.15 | 11.45 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit. It is a community bank with one reportable operating segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.